Safety and Effectiveness of Pirfenidone Combined with Carboplatin-based Chemotherapy in Patients with Idiopathic Pulmonary Fibrosis and Non-small Cell Lung Cancer: A Retrospective Cohort Study

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2020 Sep 28

PMID 32986306

Citations 13

Authors

Yuji Yamamoto

Yukihiro Yano

Tomoki Kuge

Fukuko Okabe

Mikako Ishijima

Takeshi Uenami

Masaki Kanazu

Yuki Akazawa

Toshihiko Yamaguchi

Masahide Mori

Affiliations

Soon will be listed here.

Abstract

Background: Pirfenidone is an antifibrotic agent that is potentially effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, no study has reported on its prophylactic value against chemotherapy-associated acute IPF exacerbations when combined with chemotherapy for non-small cell lung cancer (NSCLC). The present study assessed the safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy or immune checkpoint inhibitors (ICIs) in patients with IPF and NSCLC.

Methods: A total of 14 patients with IPF and NSCLC who received treatment from 2013 to 2019 were included. Patients were treated with pirfenidone combined with carboplatin and nanoparticle albumin-bound paclitaxel or S-1 as first-line chemotherapy. After confirming disease progression, patients received cytotoxic agents or ICIs, including nivolumab and pembrolizumab. Pirfenidone was continued regardless of chemotherapy changes. Overall survival (OS) and progression-free survival (PFS) for lung cancer and IPF were calculated. Moreover, the cumulative incidence of acute exacerbation of IPF (AE-IPF) within one year was evaluated.

Results: Median PFS for lung cancer was 110 days (95% confidence interval [CI]: 57-199 days), while the median OS was 362 days (95% CI: 220-526 days). Moreover, PFS for IPF was 447 days (95% CI: 286-indeterminate days), and the cumulative incidence of AE-IPF within one year was 18%. Notably, none of the patients developed AE-IPF associated with first-line chemotherapy. Among the included patients, four received ICIs, none of whom developed ICI-associated AE-IPF.

Conclusions: The present study found that pirfenidone combined with carboplatin-based regimens or ICIs might be safe first-line chemotherapy for patients with IPF and NSCLC.

Key Points: SIGNIFICANT FINDINGS OF THE STUDY: No patients with IPF and NSCLC who received pirfenidone in combination with first-line carboplatin-based chemotherapy or late-line ICIs developed acute IPF exacerbations. What this study adds Pirfenidone might have a prophylactic effect against chemotherapy-associated AE-IPF.

Citing Articles

Lung Cancer and Interstitial Lung Diseases.

Drakopanagiotakis F, Krauss E, Michailidou I, Drosos V, Anevlavis S, Gunther A Cancers (Basel). 2024; 16(16).

PMID: 39199608 PMC: 11352559. DOI: 10.3390/cancers16162837.

Acute exacerbation of postoperative idiopathic pulmonary fibrosis in a patient with lung cancer caused by invasive mechanical ventilation: A case report.

Qiu B, Zhang Z, Zhao X, Wang C, Wang T, Wang Z Heliyon. 2023; 9(11):e21538.

PMID: 38027643 PMC: 10665659. DOI: 10.1016/j.heliyon.2023.e21538.

Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges.

Abu Qubo A, Numan J, Snijder J, Padilla M, Austin J, Capaccione K Breathe (Sheff). 2023; 18(4):220147.

PMID: 36865932 PMC: 9973524. DOI: 10.1183/20734735.0147-2022.

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.

Assie J, Chouaid C, Nunes H, Reynaud D, Gaudin A, Grumberg V Ther Adv Med Oncol. 2023; 15:17588359231152847.

PMID: 36743523 PMC: 9893351. DOI: 10.1177/17588359231152847.

Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study.

Lee J, Park H, Kim S, Kim Y, Kim H BMC Pulm Med. 2023; 23(1):54.

PMID: 36739401 PMC: 9898951. DOI: 10.1186/s12890-023-02340-8.

References

Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T . Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14(5):723-8. DOI: 10.1111/j.1440-1843.2009.01547.x. View

Sekine A, Satoh H, Baba T, Ikeda S, Okuda R, Shinohara T . Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study. Cancer Chemother Pharmacol. 2016; 77(6):1245-52. DOI: 10.1007/s00280-016-3040-8. View

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Marwitz S, Turkowski K, Nitschkowski D, Weigert A, Brandenburg J, Reiling N . The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Front Oncol. 2020; 9:1550. PMC: 6985561. DOI: 10.3389/fonc.2019.01550. View

Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Kenmotsu H . Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer. Respirology. 2017; 22(7):1379-1385. DOI: 10.1111/resp.13075. View

Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View

Doebele R, Conkling P, Traynor A, Otterson G, Zhao Y, Wind S . A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2012; 23(8):2094-2102. PMC: 4141207. DOI: 10.1093/annonc/mdr596. View

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

Richeldi L, du Bois R, Raghu G, Azuma A, Brown K, Costabel U . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2071-82. DOI: 10.1056/NEJMoa1402584. View

10.

Fujiwara A, Shintani Y, Funaki S, Kawamura T, Kimura T, Minami M . Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Lung Cancer. 2017; 106:8-16. DOI: 10.1016/j.lungcan.2017.01.006. View

11.

Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K . Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia. Anticancer Res. 2015; 35(3):1697-701. View

12.

Kenmotsu H, Yoh K, Mori K, Ono A, Baba T, Fujiwara Y . Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. Cancer Sci. 2019; 110(12):3738-3745. PMC: 6890441. DOI: 10.1111/cas.14217. View

13.

Wells A, Desai S, Rubens M, Goh N, Cramer D, Nicholson A . Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003; 167(7):962-9. DOI: 10.1164/rccm.2111053. View

14.

Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A . PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019; 4(6). PMC: 6482997. DOI: 10.1172/jci.insight.125326. View

15.

Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K . Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol. 2015; 75(3):521-6. DOI: 10.1007/s00280-014-2670-y. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

18.

Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A . Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clin Lung Cancer. 2017; 19(1):e5-e9. DOI: 10.1016/j.cllc.2017.06.003. View

19.

Miura Y, Saito T, Tanaka T, Takoi H, Yatagai Y, Inomata M . Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig. 2018; 56(1):72-79. DOI: 10.1016/j.resinv.2017.09.007. View

20.

Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K . Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171(9):1040-7. DOI: 10.1164/rccm.200404-571OC. View